Lotus Pharmaceuticals (OTCMKTS:LTUS) versus Veru (NASDAQ:VERU) Head-To-Head Analysis

Veru (NASDAQ:VERU) and Lotus Pharmaceuticals (OTCMKTS:LTUS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Volatility and Risk

Veru has a beta of -0.48, indicating that its stock price is 148% less volatile than the S&P 500. Comparatively, Lotus Pharmaceuticals has a beta of -0.42, indicating that its stock price is 142% less volatile than the S&P 500.

Profitability

This table compares Veru and Lotus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veru	-376.38%	-115.99%	-66.94%
Lotus Pharmaceuticals	N/A	N/A	N/A

Institutional and Insider Ownership

47.2% of Veru shares are owned by institutional investors. 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Veru and Lotus Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.30 million	7.42	-$93.15 million	($0.34)	-2.43
Lotus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Lotus Pharmaceuticals has lower revenue, but higher earnings than Veru.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Veru and Lotus Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	0	0	4	0	3.00
Lotus Pharmaceuticals	0	0	0	0	N/A

Veru currently has a consensus price target of $4.00, suggesting a potential upside of 384.20%. Given Veru’s higher probable upside, research analysts clearly believe Veru is more favorable than Lotus Pharmaceuticals.

Summary

Veru beats Lotus Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Veru

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

About Lotus Pharmaceuticals

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.